Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series Ltd: World’s leading Event Organizer

Back

Randall J Bjork

Randall J Bjork

Lotus Health, USA

Title: The neuropharmacological and nonpharmacological treatment of dementia

Biography

Randall Bjork is a neurologist from North Dakota who has been in practice for over three decades, mostly in Colorado, emphasizing humane and ethical dementia care. Twenty years ago, he advocated economy-of-scale dementia care with the concept of Lotus Health, which he will present here at our Dubai conference. He was involved in dementia treatment research from the early days of Cognex. He has conducted research with Aricept treatment and MRS evaluation in Down-Alzheimer patients. Dr. Bjork is co-author of a paper being presented here by his Swedish colleague, Dr. Lindau, from The University of Stockholm. He is now involved in a multi-center ketamine treatment protocol of treatment-resistant depression and post-traumatic stress disorder. He has lectured worldwide, contributed to the literature of cardiac arrest, stroke, myoclonus, Alzheimer disease, prionoses and has recently published a children's book, The ABCs of You, Volume I, available on Amazon. He has supervised mission medical work in Costa Rica and Nepal. He is an avid motorcyclist, restaurateur, cancer survivor and retired helicopter pilot.

Abstract

The neuropharmacological treatment of the dementing illnesses, primarily senile dementia of the Alzheimer type, has emphasized central cholinergic augmentation or glutamatergic modulation for the past few decades. More enlightened and, perhaps, disease-modifying strategies have been considered since late last millennium—some of which are close to coming into the clinical arena. Advances in slowing or reversing the progression of neurodegeneration have not, regrettably, proceeded pari passu, with significant developments in biomarker-based diagnosis of the neurodegenerative diseases. Senile dementia of the Alzheimer type, parkinsonian disorders, diffuse Lewy body disease, fronto-temporal dementia, cortico-basal degeneration and the prionoses can be diagnosed with confidence ante-mortem, but current treatments have been, at the very least, clinically disappointing and, most disturbing, a fountain of false hope for patients and their families. This schism between intellectually exciting early diagnostic measures and worthwhile disease-modifying treatments has led to an ethical dilemma: Should a patient be subjected to an early diagnosis of a neurodegenerative disorder when there is no meaningful treatment? This lecture will present a review of biomarkers and their current place in research and clinical practice, including implications of amyloid/tau imaging. Potential disease-modifying treatments of the future will be presented, with discussion of hypothesized molecular mechanisms of action and potential economic impact. An economy-of-scale, futuristic view of ethical and humane long-term care for those afflicted with neurodegenerative diseases will be presented, because the current model of residential care is not sustainable.